Announcements Trials
Browse Landscape

Phase

Phase 2 31Phase 1 21Phase 1/2 11Phase 3 9Phase NA 5Phase 2/3 1

Status

Suspended 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 4Sarcoma 3Head & Neck 3Tumor-Agnostic 2Other hematologic neoplasm 2Lymphoid 2CNS 2Thoracic 1Plasma cell 1Other 1Gynecologic 1Genitourinary 1

Conditions

Lung Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenocarcinoma of Lung 1

Interventions

Pemetrexed 23Carboplatin 21Cisplatin 20pembrolizumab 15Docetaxel 14Paclitaxel 10Gemcitabine 8Drug Therapy 7Bevacizumab 7Gefitinib 5Radiotherapy 4Magnetic Resonance Spectroscopy 4Erlotinib Hydrochloride 4130-nm albumin-bound paclitaxel 4cemiplimab 3atezolizumab 3anlotinib 3Dexamethasone 3dexamethasone acetate 2dexamethasone 21-phosphate 2cobimetinib 2auricularum 2aumolertinib 2apatinib 2Vemurafenib 2Topotecan 2Temozolomide 2Surgical Procedures, Operative 2Standard of Care 2Specimen Handling 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Radiation × Thoracic × Clear all
NCT04929041 2026-05-13

Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative

National Cancer Institute (NCI)

Phase 2/3 Suspended
427 enrolled
Thoracic

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡